Tuesday, April 22, 2014 3:44:16 PM
I understand what you mean, but you are sorta contradicting yourself.
They are all part of the same thing. We are not raising eggs to produce worms. We are raising eggs to produce cocoons.
Yes each piece will have its percentage but you do not base your cocoon percentage on how many moths you have.
The cocoon is the end product. The eggs are a starting product.
There is a math problem in there.
We need 1M worms for a ton of silk. 10% of the worms will die and 20% of the eggs will not make worms. In the end your cocoon yield is 70% with a 30% death rate.
So now you know you actually need 1.2M eggs to get a ton of cocoons.
Notice you do not need a set amount of worms. Just eggs.
There is also a math problem involved in the moths.
They produce 100 eggs each so you need to have 1200 moths to produce 1.2M eggs. But again no worms. The worms are incorporated into the starting egg count.
All that matters in each phase is the beginning and ending.
Eggs and cocoons.
Moth and eggs.
They can keep track of the worms deaths to help improve the problem by realizing that the worms are all dying off at a set stage but it is all about the end result.
A 70% viable cocoon rate means 70 cocoons for every 100 eggs you start with.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM